News

Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.
Why Recursion Pharmaceuticals Stock Got Mashed on Monday
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.95, marking a -5.71% move from the previous day.